- Home
- NUVL vs IAG Comparison
NUVL vs IAG Comparison
Compare NUVL & IAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- IAG
- Stock Information
- Founded
- NUVL 2017
- IAG 1990
- Country
- NUVL United States
- IAG Canada
- Employees
- NUVL N/A
- IAG N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- IAG Precious Metals
- Sector
- NUVL Health Care
- IAG Basic Materials
- Exchange
- NUVL Nasdaq
- IAG Nasdaq
- Market Cap
- NUVL 6.5B
- IAG 7.1B
- IPO Year
- NUVL 2021
- IAG 1996
- Fundamental
- Price
- NUVL $98.17
- IAG $11.66
- Analyst Decision
- NUVL Strong Buy
- IAG Buy
- Analyst Count
- NUVL 11
- IAG 4
- Target Price
- NUVL $121.45
- IAG $15.25
- AVG Volume (30 Days)
- NUVL 527.5K
- IAG 13.6M
- Earning Date
- NUVL 10-30-2025
- IAG 11-04-2025
- Dividend Yield
- NUVL N/A
- IAG N/A
- EPS Growth
- NUVL N/A
- IAG 452.66
- EPS
- NUVL N/A
- IAG 1.37
- Revenue
- NUVL N/A
- IAG $1,966,800,000.00
- Revenue This Year
- NUVL N/A
- IAG $58.73
- Revenue Next Year
- NUVL N/A
- IAG $17.59
- P/E Ratio
- NUVL N/A
- IAG $8.49
- Revenue Growth
- NUVL N/A
- IAG 57.81
- 52 Week Low
- NUVL $55.54
- IAG $4.89
- 52 Week High
- NUVL $104.90
- IAG $14.67
- Technical
- Relative Strength Index (RSI)
- NUVL 60.96
- IAG 43.82
- Support Level
- NUVL $90.00
- IAG $10.92
- Resistance Level
- NUVL $99.94
- IAG $11.95
- Average True Range (ATR)
- NUVL 5.06
- IAG 0.60
- MACD
- NUVL 0.69
- IAG -0.32
- Stochastic Oscillator
- NUVL 66.81
- IAG 19.84
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About IAG Iamgold Corporation
Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.